Home › Immunoblastic Lymphadenopathy
Immunoblastic Lymphadenopathy clinical trials recruiting in the U.S.
9 studies for Immunoblastic Lymphadenopathy are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY5 studies
- Miami, FL4 studies
- Houston, TX4 studies
- Durham, NC4 studies
- Chicago, IL4 studies
- New Haven, CT3 studies
- Edison, NJ3 studies
- Baldwin Park, CA3 studies
- Atlanta, GA3 studies
- Columbus, OH3 studies
- Boston, MA3 studies
- St. Louis, MO3 studies
- Rochester, MN3 studies
- Ann Arbor, MI3 studies
By state
- California4 studies
- Connecticut3 studies
- Florida4 studies
- Georgia3 studies
- Illinois4 studies
- Maryland3 studies
- Massachusetts3 studies
- Michigan4 studies
- Minnesota3 studies
- Missouri3 studies
- New Jersey4 studies
- New York5 studies
- North Carolina4 studies
- Ohio4 studies
- Pennsylvania4 studies
- Texas4 studies
Recently updated studies
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06561048A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06393738Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04803201A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 24, 2026 · NCT07055477Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT03017820A Registry for People With T-cell Lymphoma
RecruitingObservational study
All ages · All sexes · Updated May 20, 2026 · NCT05978141Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 27, 2025 · NCT01137643Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2025 · NCT04234048From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.